Oscar R Durón

👏🏼

Empagliflozin, the kidney, and what we still don’t understand — NephJC NephJC short on an empagliflozin meta-analysis

The latest empadata dump: @nephroseeker.medsky.social writes up a #NephJC short on the meta analysis

www.nephjc.com/news/2025/10...

Congratulations to all the Interns of this new program! Looking forward to follow their journey.

Legends!

A one year delay in diagnosis of #hypertension!

Clear illustration of the importance of measuring BP in both arms

www.ahajournals.org/doi/10.1161/... in @ahajournals.bsky.social Hypertension

This. 😇

Open-Label, Randomized, Controlled, Crossover Trial on the Effect of Dapagliflozin in Patients With ADPKD Receiving Tolvaptan Although dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, delays the progression of chronic kidney disease (CKD), its effect on patients with autosomal dominant polycystic kidney dis...

Our topic:
Use of dapagliflozin (SGLT2 inhibitor) in patients with autosomal dominant polycystic kidney disease (ADPKD) concurrently on tolvaptan therapy. There are no conflicts of interest.
#MedSky #NephSky
Article: www.kireports.org/article/S2468-0249(25)00048-8/fulltext

The first KDIGO ADPKD guideline — NephJC The KDIGO ADPKD guideline is a result of a decade of global collaboration between physicians, researchers, advocates, and patients. 240 pages summarized in only 2 pictures, made by Cristina Popa .

Check out the VA from @nephroseeker.medsky.social 👀
Join us tonite at 9pm EST to discuss @kdigo.org ADPKD 2025 guidelines 📚 #NephSky#MedSky #NephJC
www.nephjc.com/news/2025/kdigo-adpkd-va

Not lastly, #NephSky #MedSky

✨This year we try something new: #nephjc internship

If curious, wanna apply, need to be part of our world-wide community, apply 👇

#NephMadness 2025: Renal Denervation in Hypertension: Fad or Fixture? Submit your picks! | @NephMadness | @nephmadness.bsky.social | NephMadness 2025   Swapnil Hiremath Swapnil Hiremath is a Professor at the University of Ottawa and an Associate Scientist at the Otta…

Drugs or devices?

For #NephMadness, I make my choice

ajkdblog.org/2025/03/19/n...

Let’s see if the wise #BlueRibbonFail panel likes similar sensible solutions!

Need weekend plans?

Catch up on all the #NephMadness 2025 regions:
-Resistant Hypertension
-Obesity
-Green House
-Minimal Change Disease
-Disaster Nephrology
-Genetics
-Hemodialysis
-CAR-T for Kidney Disease

Happy reading!

bit.ly/4iMNijV

I order it in resistant hypertension or young patients with hypertension. I admit I have a wonderful endocrinologist team who helps me interpret results and go further with more tests if necessary.

That’s where I am coming from. Thank you for your input on this.

Do this interfere on your decision making? Having proteinuria <1 gr or >2 gr can make a difference in some patients.

That’s a very good point. Thank you.

Thank you very much. Very helpful! 🙆🏽‍♂️

Now that we are in the subject, do you have any specific use for Cr excretion? Do you consider any specific value for “high” and “low” or just go with what your lab parameters?

I’ll take a look. Thank you very much!

BMI > 30 but no hyperflitration in eGFR.

All I found was this study, which concludes that there is a strong correlation between both tests. In my clinical practice, this is not the case. I want to hear everyone’s thought on this. Here to learn!

www.revistanefrologia.com/es-pdf-X0211...

A question to all Nephrologists, how do you approach the difference in proteinuria between samples of spot urine and 24 hr urine?

In this example:
- Spot Urine Alb/Cr ratio: 938 mg/g
- 24 hrs: 2,177 mg/24 hrs

My calculations for Alb/Cr ratio in 24 hr is 985 mg/g

#AskRenal

🤩

🎨The visual abstract made by @drnikhil.bsky.social

#NephSKy #MedSKy, tonight #NephJC goes with an oldie but still goldie topic: RASi in advanced CKD

⏰ Same hour, 9 pm EST

www.nephjc.com/news/2024/12...

Thank you for the insight @jamiekwillows.bsky.social , it definitely spiced up the discussion. And thank you to all the @nephjc.bsky.social team for having my back on this one. I deeply appreciate it and feel flattered to have the opportunity to participate.

ACEing the management of advanced CKD — NephJC This week we come to meta-analyse, strikingly late, the cornerstone of all CKD treatments. Are you still in doubt? We need ACEing CKD to the end of GFR, and beyond

Is it ever too late to start RAS inhibitors in CKD?

www.nephjc.com/news/aceing-... from @osduvar.bsky.social

Join us this week to discuss on #NephJC

ACEing the management of advanced CKD — NephJC This week we come to meta-analyse, strikingly late, the cornerstone of all CKD treatments. Are you still in doubt? We need ACEing CKD to the end of GFR, and beyond

Afraid of RASi on advanced CKD? Should we initiate ACEi and ARBs in stage 4 CKD? Is it safe? Is it worth the risk? Find the answers in this week’s #NephJC blogpost about the most recent meta-analysis on the subject.

Spoiler: Keep Calm and Aceit!

www.nephjc.com/news/aceing-...

This is the way.

Yeah. I would.

I wouldn’t mind doing my Residency again 😅.

Thanks for sharing.